Cargando…
Alzheimer’s disease biomarkers in cerebrospinal fluid are stable with the Elecsys immunoassay to most pre-analytical influencing factors except freezing at -80 °C
BACKGROUND: Alzheimer´s disease is considered a neurodegenerative disease and is diagnosed by exclusion, while the detection of specific cerebrospinal fluid (CSF) biomarkers, namely amyloid-beta (Aβ) peptides Aβ1–42 (Aß42), phospho-tau (181P; P-tau), and total-tau (T-tau), has been shown to improve...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10308606/ https://www.ncbi.nlm.nih.gov/pubmed/37381021 http://dx.doi.org/10.1186/s42466-023-00257-5 |
_version_ | 1785066279771570176 |
---|---|
author | Konen, Franz Felix Maier, Hannah Benedictine Neyazi, Alexandra Bleich, Stefan Neumann, Konstantin Skripuletz, Thomas |
author_facet | Konen, Franz Felix Maier, Hannah Benedictine Neyazi, Alexandra Bleich, Stefan Neumann, Konstantin Skripuletz, Thomas |
author_sort | Konen, Franz Felix |
collection | PubMed |
description | BACKGROUND: Alzheimer´s disease is considered a neurodegenerative disease and is diagnosed by exclusion, while the detection of specific cerebrospinal fluid (CSF) biomarkers, namely amyloid-beta (Aβ) peptides Aβ1–42 (Aß42), phospho-tau (181P; P-tau), and total-tau (T-tau), has been shown to improve diagnostic accuracy. Recently, a new generation of sample tubes (Sarstedt false-bottom tubes) for the Elecsys CSF immunoassay for the determination of Alzheimer´s disease biomarkers in CSF was introduced, promising better measurability. However, the pre-analytic influencing factors have not yet been sufficiently investigated. METHODS: In 29 patients without Alzheimer’s disease diagnosis, CSF concentrations of Aß42, P-tau and T-tau were examined in native CSF and after different influencing interventions using the Elecsys immunoassay test method. The following influencing factors were analyzed: contamination with blood (10,000 and 20,000 erythrocytes/µl CSF), 14-day storage at 4 °C, blood contamination of CSF and 14-day storage at 4 °C, 14-day freezing at -80 °C in Sarstedt tubes or glass vials, 3-month intermediate storage at -80 °C in glass vials. RESULTS: Both storage at -80 °C for 14 days in Sarstedt false-bottom tubes and in glass vials and storage at -80 °C for 3 months in glass vials resulted in significant decreases in Aß42 (13% after 14 days in Sarstedt and 22% in glass vials, 42% after 3 months in glass vials), P-tau (9% after 14 days in Sarstedt and 13% in glass vials, 12% after 3 months in glass vials) and T-tau (12% after 14 days in Sarstedt and 19% in glass vials, 20% after 3 months in glass vials) concentrations in CSF. No significant differences were found for the other pre-analytical influencing factors. CONCLUSIONS: Measurements of the concentrations of Aß42, P-tau, and T-tau in CSF with use of the Elecsys immunoassay are robust to the pre-analytical influencing factors of blood contamination and duration of storage. Freezing at -80 °C results in significant reduction of biomarker concentrations regardless of the storage tube and must be considered in retrospective analysis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s42466-023-00257-5. |
format | Online Article Text |
id | pubmed-10308606 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-103086062023-06-30 Alzheimer’s disease biomarkers in cerebrospinal fluid are stable with the Elecsys immunoassay to most pre-analytical influencing factors except freezing at -80 °C Konen, Franz Felix Maier, Hannah Benedictine Neyazi, Alexandra Bleich, Stefan Neumann, Konstantin Skripuletz, Thomas Neurol Res Pract Research Article BACKGROUND: Alzheimer´s disease is considered a neurodegenerative disease and is diagnosed by exclusion, while the detection of specific cerebrospinal fluid (CSF) biomarkers, namely amyloid-beta (Aβ) peptides Aβ1–42 (Aß42), phospho-tau (181P; P-tau), and total-tau (T-tau), has been shown to improve diagnostic accuracy. Recently, a new generation of sample tubes (Sarstedt false-bottom tubes) for the Elecsys CSF immunoassay for the determination of Alzheimer´s disease biomarkers in CSF was introduced, promising better measurability. However, the pre-analytic influencing factors have not yet been sufficiently investigated. METHODS: In 29 patients without Alzheimer’s disease diagnosis, CSF concentrations of Aß42, P-tau and T-tau were examined in native CSF and after different influencing interventions using the Elecsys immunoassay test method. The following influencing factors were analyzed: contamination with blood (10,000 and 20,000 erythrocytes/µl CSF), 14-day storage at 4 °C, blood contamination of CSF and 14-day storage at 4 °C, 14-day freezing at -80 °C in Sarstedt tubes or glass vials, 3-month intermediate storage at -80 °C in glass vials. RESULTS: Both storage at -80 °C for 14 days in Sarstedt false-bottom tubes and in glass vials and storage at -80 °C for 3 months in glass vials resulted in significant decreases in Aß42 (13% after 14 days in Sarstedt and 22% in glass vials, 42% after 3 months in glass vials), P-tau (9% after 14 days in Sarstedt and 13% in glass vials, 12% after 3 months in glass vials) and T-tau (12% after 14 days in Sarstedt and 19% in glass vials, 20% after 3 months in glass vials) concentrations in CSF. No significant differences were found for the other pre-analytical influencing factors. CONCLUSIONS: Measurements of the concentrations of Aß42, P-tau, and T-tau in CSF with use of the Elecsys immunoassay are robust to the pre-analytical influencing factors of blood contamination and duration of storage. Freezing at -80 °C results in significant reduction of biomarker concentrations regardless of the storage tube and must be considered in retrospective analysis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s42466-023-00257-5. BioMed Central 2023-06-29 /pmc/articles/PMC10308606/ /pubmed/37381021 http://dx.doi.org/10.1186/s42466-023-00257-5 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Article Konen, Franz Felix Maier, Hannah Benedictine Neyazi, Alexandra Bleich, Stefan Neumann, Konstantin Skripuletz, Thomas Alzheimer’s disease biomarkers in cerebrospinal fluid are stable with the Elecsys immunoassay to most pre-analytical influencing factors except freezing at -80 °C |
title | Alzheimer’s disease biomarkers in cerebrospinal fluid are stable with the Elecsys immunoassay to most pre-analytical influencing factors except freezing at -80 °C |
title_full | Alzheimer’s disease biomarkers in cerebrospinal fluid are stable with the Elecsys immunoassay to most pre-analytical influencing factors except freezing at -80 °C |
title_fullStr | Alzheimer’s disease biomarkers in cerebrospinal fluid are stable with the Elecsys immunoassay to most pre-analytical influencing factors except freezing at -80 °C |
title_full_unstemmed | Alzheimer’s disease biomarkers in cerebrospinal fluid are stable with the Elecsys immunoassay to most pre-analytical influencing factors except freezing at -80 °C |
title_short | Alzheimer’s disease biomarkers in cerebrospinal fluid are stable with the Elecsys immunoassay to most pre-analytical influencing factors except freezing at -80 °C |
title_sort | alzheimer’s disease biomarkers in cerebrospinal fluid are stable with the elecsys immunoassay to most pre-analytical influencing factors except freezing at -80 °c |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10308606/ https://www.ncbi.nlm.nih.gov/pubmed/37381021 http://dx.doi.org/10.1186/s42466-023-00257-5 |
work_keys_str_mv | AT konenfranzfelix alzheimersdiseasebiomarkersincerebrospinalfluidarestablewiththeelecsysimmunoassaytomostpreanalyticalinfluencingfactorsexceptfreezingat80c AT maierhannahbenedictine alzheimersdiseasebiomarkersincerebrospinalfluidarestablewiththeelecsysimmunoassaytomostpreanalyticalinfluencingfactorsexceptfreezingat80c AT neyazialexandra alzheimersdiseasebiomarkersincerebrospinalfluidarestablewiththeelecsysimmunoassaytomostpreanalyticalinfluencingfactorsexceptfreezingat80c AT bleichstefan alzheimersdiseasebiomarkersincerebrospinalfluidarestablewiththeelecsysimmunoassaytomostpreanalyticalinfluencingfactorsexceptfreezingat80c AT neumannkonstantin alzheimersdiseasebiomarkersincerebrospinalfluidarestablewiththeelecsysimmunoassaytomostpreanalyticalinfluencingfactorsexceptfreezingat80c AT skripuletzthomas alzheimersdiseasebiomarkersincerebrospinalfluidarestablewiththeelecsysimmunoassaytomostpreanalyticalinfluencingfactorsexceptfreezingat80c |